BOPA 2018 | Understanding the NICE economic evaluation process
Understanding the NICE economic evaluation process for new oncology drugs and technologies, is an important skill for Oncology Pharmacists to have as it can help them to make the best decisions as part of their clinical practice. Rachel Elliott, BPharm, PhD, FRPharmS, from the University of Manchester, Manchester, UK, explains the various factors considered when evaluating new treatments, including cost, quality of life and efficacy. This interview was recorded at the British Oncology Pharmacy Association (BOPA) Annual Symposium 2018, held in Birmingham, UK.
Get great new content delivered to your inboxSign up